It reveals the toxic mechanism of chromycin and develops a promising class of anti-tuberculosis drugs

Tuberculosis (TB) is a disease caused by Mycobacterium tuberculosis, which kills about 1.3 million people worldwide each year. The vast majority of deaths occur in developing countries, where poor sanitation and poor access to health services make the problem even worse. Antibiotic resistance is becoming an important issue for TB because many pathogenic strains are resistant to a range of available drugs, and some of these strains are resistant to all of these antibiotics.
is an antibiotic produced by several bacterial types, but it is not suitable for humans because it is also toxic to animal cells.
a new study, researchers from research institutions such as the University of Oxford in the United Kingdom studied the toxicity formation mechanism of lysycin and found that it acted on the gene DPAGT1, which produces an enzyme involved in the biosynthetic synthesis of glycogen. The findings were recently published in the Journal of Cell under the title "Structures of DPAGT1 Explain Glycosylation Disease Mechanisms and Advance TB Antibiotic Design".
by studying the interaction between chromycin and the protein, the researchers were able to understand how it worked on cells. They also altered the structure of chromycin to create new similarity, several of which effectively treat tuberculosis in mice.
Professor Benjamin Davis, of the Department of Chemistry at the University of Oxford, said: "The threat of TB is growing because we are running out of drugs to treat it. An exciting result of this study is the development of a promising new class of antimicrobial drugs. (Bio Valley)